Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.4000
-0.0250 (-5.88%)
Mar 31, 2025, 2:12 PM EDT - Market open
Bolt Biotherapeutics Revenue
In the year 2024, Bolt Biotherapeutics had annual revenue of $7.69M, down -2.36%.
Revenue (ttm)
$7.69M
Revenue Growth
-2.36%
P/S Ratio
2.11
Revenue / Employee
$76,900
Employees
100
Market Cap
15.34M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BOLT News
- 5 days ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 6 days ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 6 weeks ago - Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. - GlobeNewsWire
- 5 months ago - Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm - Accesswire
- 7 months ago - Bolt Biotherapeutics Announces Changes to its Board of Directors - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm - Accesswire